{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:05Z","timestamp":1788845465912,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Although renin-angiotensin system inhibitors (RASIs) slow the progression of chronic kidney disease, these agents are frequently discontinued if acute declines in the estimated glomerular filtration rate (eGFR) occur after their initiation.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the risk for cardiovascular, kidney, and mortality outcomes associated with discontinuation vs continuation of RASIs in patients with an acute decline in eGFR after RASI initiation.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study using a target trial emulation approach leveraged electronic health record data from the Manitoba Centre for Health Policy that were linked to vital statistics in the province of Manitoba, Canada. Propensity score matching was applied to identify adults (aged \u226518 years) receiving new prescriptions for RASIs between January 1, 2008, and December 31, 2021, who subsequently had an eGFR decline of more than 15% within 90 days of the prescription. Data were analyzed between January 14, 2024, and January 22, 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n RASI discontinuation (vs continuation) defined based on whether a RASI prescription was refilled within 90 days after a decline in eGFR of 15% had occurred.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes of end-stage kidney disease (ESKD) or death, and secondary outcomes of major adverse cardiovascular events (MACEs) (including myocardial infarction, heart failure, stroke, or cardiovascular mortality) or acute kidney injury (AKI) were examined after 180 days. Cox proportional hazards models were used to compare the exposure with the outcomes in an intention-to-treat approach.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 4233 patients (mean [SD] age, 64.6 [16.2] years; 2697 male [51.1%]) who had a more than 15% decline in eGFR after starting a RASI were included; 1411 patients (33.3%) discontinued RASIs, and 2822 (66.6%) continued RASIs . Patients who discontinued vs continued RASIs had a higher risk of death (hazard ratio [HR], 1.23; 95% CI, 1.07-1.41) and ESKD (HR, 1.74; 95% CI, 1.28-2.38). Their risk of MACEs (HR, 1.13; 95% CI, 0.99-1.28) and AKI (HR, 1.11; 95% CI, 0.90-1.37) was not significantly higher.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that discontinuation of RASIs after an acute decline in eGFR was associated with ESKD and death compared with continuing RASIs. These findings suggest that further study is needed to understand reasons for frequent discontinuation of RASIs and devise strategies to improve their persistent use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.3680","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:21Z","timestamp":1774625421000},"page":"e263680","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate"],"prefix":"10.1001","volume":"9","author":[{"given":"Elaine","family":"Ku","sequence":"first","affiliation":[{"name":"Division of Nephrology, Departments of Medicine and Pediatrics, University of California, San Francisco"},{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"},{"name":"Section of Nephrology, Department of Internal Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranveer","family":"Brar","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Sarnak","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"5","key":"zoi260147r1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"3","key":"zoi260147r2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","article-title":"Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.","volume":"91","author":"Clase","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"zoi260147r3","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"zoi260147r4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.kint.2016.11.019","article-title":"Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications.","volume":"91","author":"Weir","year":"2017","journal-title":"Kidney Int"},{"issue":"12","key":"zoi260147r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012690","article-title":"Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.","volume":"6","author":"Mansfield","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"zoi260147r6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","article-title":"Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus.","volume":"73","author":"Ohkuma","year":"2019","journal-title":"Hypertension"},{"issue":"10","key":"zoi260147r7","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: a UK population-based study.","volume":"84","author":"Mahmoudpour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"zoi260147r8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"zoi260147r9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent Reporting of Observational Studies Emulating a Target Trial-the TARGET statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"15","key":"zoi260147r10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035177","article-title":"Acute declines in estimated glomerular filtration rate in patients treated with benazepril and hydrochlorothiazide versus amlodipine and risk of cardiovascular outcomes.","volume":"13","author":"Ku","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"zoi260147r11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1681\/ASN.0000000000000426","article-title":"Association between acute declines in eGFR during renin-angiotensin system inhibition and risk of adverse outcomes.","volume":"35","author":"Ku","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"zoi260147r12","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease.","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi260147r13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial.","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"4S","key":"zoi260147r14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"11","key":"zoi260147r15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1681\/ASN.0000000000000473","article-title":"Stop sitting on our RAASes: get moving with the most effective care for our patients.","volume":"35","author":"Lafayette","year":"2024","journal-title":"J Am Soc Nephrol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847024\/ku_2026_oi_260147_1774024999.78434.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:21Z","timestamp":1774625421000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.3680","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}